One Place News
A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 repaired dangerous DNA damage, reduced inflammation, and targeted multiple disease-related pathways instead of focusing on just amyloid or tau. Since it has already cleared an initial human safety trial, researchers believe it could move more quickly into Alzheimer’s clinical testing.
One Place NewsAn international study found that finerenone slows kidney function decline and reduces the risk of serious kidney and cardiovascular complications in people with chronic kidney disease who do not have…
One Place NewsA new experimental treatment may have found a way to outsmart glioblastoma’s toughest defense: the blood-brain barrier. Researchers used sugar-coated nanoparticles to ferry genetic instructions that restore a key tumor-suppressing…
